An international research team has uncovered how LUCA, the last common ancestor of all life on Earth, split into the first two branches of organisms—bacteria and archaea—allowinglife to thrive innew conditions and spread to other biomes.

Scientists from the Institute of Molecular Evolution at Heinrich Heine University Düsseldorf (HHU) led the research, revealing their findings in a recent paper published in Science Advances, investigating these early cells’ metabolisms.

The team discovered that the chemical reactions and energy sources behind these two types of cells told unique stories of separate evolutions, in new work that sheds light on the primordial processes that gave rise to some of Earth’s first free-living cells.

Life on Earth Begins

Roughly four billion years ago, life on Earth emerged as the first cells formed, most likely at hydrothermal vents, before evolving to explore new biomes. 

“We would see two very different kinds of cells emerging, pioneer bacteria and pioneer archaea, making their first attempts at life outside the confines of a hydrothermal vent,” said lead author Natalia Mrnjavac, a biologist at the University of Düsseldorf.

The new study investigated protein structures, chemical reactions, and genomes involved in the evolution of these early free-living cells.

“These comparisons are giving us unprecedented insights into the phase of evolution when metabolism catalysed by enzymes was arising from spontaneous reactions catalysed by metals in the Earth’s crust,” said senior author William Martin, a Düsseldorf biologist.

Metabolism and Evolution

Among the new work’s major findings is a consideration of the entire set of 420 chemical reactions involved in metabolism that produce amino acids, RNA bases, and vitamins from the raw materials of hydrogen, ammonia, and carbon dioxide. 

These reactions are preserved for modern researchers inside the genetic code, allowing the team to make a surprising discovery: about half of LUCA’s reactions were catalyzed by environmental metals instead of enzymes produced by the organism itself.

“Metals that naturally occur in hydrothermal vents can replace a surprisingly large number of enzymes in metabolism,” said co-author Harun Tüysüz, an inorganic chemist from the Max-Planck-Institut für Kohlenforschung and the IMDEA Materials Institute in Madrid.

In this study, the team reconstructed catalysis evolution from metal-only to a metal-enzyme hybrid present in LUCA, and finally to the divergence of the bacterial and archaeal lineages. This evolution helped life move on from the hydrothermal vents inhabited by the first cells by replacing the inorganic catalysts provided by that environment with new enzymes. 

“We can see cases where the ancestors of bacteria and archaea independently evolved structurally distinct enzymes to catalyse the same essential metabolic reaction,” Mrnjavac explained, adding that “such parallel inventions could have paved the way to the independent emergence of free-living bacteria and archaea.”

The Energy for Life on Earth

A primary question involves what supplied the energy driving metabolic reactions in early life on Earth. A compound named ATP is the primary metabolic driver in most organisms today, but it comes from enzymes and is not present in hydrothermal vents. The researchers identified a new energy source in palladium, a natural catalyst used by chemists and also plentiful in hydrothermal vents.

“When we react phosphite, a form of phosphorus that naturally occurs in hydrothermal vents, with organic compounds, we get metabolic phosphorylation reactions overnight in water. Phosphite and palladium replace ATP and enzymes; it’s amazing, and it makes early evolution a lot easier to grasp,” Schlikker said.

Understanding the interconnection between so many reactions presents a significant mathematical challenge. For this reason, the team included not just biologists, but network scientists tasked with ordering the reactions by their complexity, which the researchers hoped would indicate the sequence in which they evolved. Using a machine learning algorithm, the team discovered that a clear order did appear to exist.

“The new data leave only one conclusion,” Martin concluded. “The bacteria and archaeal lineages made the transition to the free-living state independently. Only free-living cells are alive.”

“Let’s call it by name,” Martin added. “We are looking at one origin of the genetic code, but two origins of life.”

The paper, “Intermediate Stages in the Origin of Metabolism at a Phosphorylating Hydrothermal Vent,” appeared in Science Advances on August 5, 2026.

Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org.

A common complication of early birth is being thrust into a medical debate that reaches far beyond the neonatal intensive-care unit: how low is too low when a late preterm baby’s blood glucose falls, and what—if anything—does that episode mean years later? A new article in Pediatric Research examines late preterm hypoglycemia through the lens of long-term evidence, highlighting why a seemingly brief metabolic disturbance has become one of neonatology’s most closely watched questions.

Late preterm infants are typically born between 34 weeks and 36 weeks plus six days of gestation. They often appear stronger and more mature than very preterm babies, but their brains, hormone systems and feeding abilities are still developing. After birth, glucose levels can drop as the infant transitions from a constant placental supply to intermittent feeding. Immature glycogen stores, limited fat reserves, difficulty coordinating sucking and swallowing, and illness-related stress can all increase the risk of hypoglycemia.

Glucose is the brain’s primary energy source during early life, making neonatal hypoglycemia biologically concerning. When glucose delivery falls, the brain may initially compensate by using alternative fuels, including lactate and ketone bodies. If the shortage is severe, prolonged or repeatedly missed, however, energy production can become insufficient. This may interfere with neuronal signaling and, in extreme cases, contribute to cellular injury. The challenge is that many affected newborns show no obvious symptoms, while symptomatic infants may display only subtle signs such as jitteriness, poor feeding, lethargy, temperature instability or apnea.

The article by U. Felderhoff-Müser focuses attention on a crucial gap between immediate treatment and long-term certainty. Hospitals commonly screen infants considered vulnerable to hypoglycemia, including late preterm newborns, and intervene with feeding, buccal dextrose gel or intravenous glucose when indicated. These measures are designed to restore glucose quickly and prevent neurological stress. Yet the threshold used to define hypoglycemia is not a universal biological line. It is a clinical value shaped by gestational age, postnatal age, symptoms, measurement method and the balance between avoiding harm and preventing unnecessary intervention.

That uncertainty has made long-term follow-up essential. Researchers have investigated whether neonatal hypoglycemia is associated with later problems involving cognition, executive function, attention, language, motor coordination and school performance. Some studies have reported higher risks after severe, recurrent or prolonged episodes, while others have found limited or inconsistent effects, particularly when low glucose was detected and treated promptly. The differences may reflect more than glucose itself: prematurity, fetal growth restriction, maternal diabetes, infection, respiratory illness and socioeconomic conditions can independently influence neurodevelopment.

This is one reason the evidence remains difficult to interpret. Most long-term studies are observational, meaning researchers cannot randomly assign infants to experience different glucose levels. Instead, they compare children who had hypoglycemia with those who did not, while attempting to account for other medical and social factors. Even sophisticated statistical adjustments may not eliminate hidden confounding. In addition, studies use different definitions of hypoglycemia, different monitoring schedules and different ages or tools for developmental testing, making direct comparisons challenging.

The timing and pattern of low glucose may be as important as the lowest recorded number. A single short episode may carry a different biological significance from repeated episodes or an extended period below a treatment threshold. Continuous glucose monitoring has raised further questions by revealing fluctuations that intermittent heel-stick testing can miss, although sensor accuracy in newborns and the clinical meaning of every detected dip are still being evaluated. The emerging picture is therefore more complex than a simple division between “normal” and “abnormal.”

For clinicians and families, the practical message is not to dismiss hypoglycemia or to assume that every low reading predicts disability. Instead, the long-term evidence supports careful surveillance of infants at risk, rapid confirmation of abnormal results, and treatment strategies that protect the brain without disrupting feeding or exposing babies to unnecessary interventions. Developmental follow-up may be particularly important for infants with severe or recurrent episodes, neurological symptoms, or multiple additional risk factors. Such monitoring can identify difficulties early, when speech, occupational or educational support may have the greatest effect.

The discussion also underscores the need for better research. Future studies will need standardized glucose definitions, precise records of duration and recurrence, improved measurement technologies and follow-up extending into school age and adolescence. Researchers must also distinguish the effects of hypoglycemia from the conditions that caused it and examine outcomes beyond a single global developmental score. Felderhoff-Müser’s review places late preterm hypoglycemia in that broader scientific context: a common neonatal event whose immediate management is well established, but whose long-term consequences still demand careful, nuanced investigation.

Subject of Research: Late preterm hypoglycemia and its long-term neurodevelopmental evidence

Article Title: Late preterm hypoglycemia through the lens of long-term evidence

Article References: Felderhoff-Müser, U. “Late preterm hypoglycemia through the lens of long-term evidence.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05316-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05316-6

Keywords: late preterm infants, neonatal hypoglycemia, blood glucose, neurodevelopment, brain health, newborn care, long-term outcomes

Short-chain fatty acids (SCFAs)—especially acetate, propionate, and butyrate—are produced when gut microbes ferment carbohydrates that the human body cannot digest. Over the past decade, these small molecules have moved beyond being viewed as simple fuel. Instead, they are now recognized as signalling messengers that help tune metabolism, shape immune responses, and support physiological balance across organs. A new review in Nature Metabolism brings together scattered findings to clarify how SCFAs are made, how they are processed in the body, and why they matter for health.

The article emphasizes that SCFA production is not uniform. It depends on which microbial communities inhabit the gut, which dietary substrates reach the colon, and how microbes share resources through cross-feeding. When multiple bacterial species coordinate, fermentation pathways can shift, increasing the output of particular SCFAs. In that way, the “hardware” of the microbiome and the “inputs” provided by diet jointly determine the chemical signals generated in the intestine.

After their formation, SCFAs are handled by host tissues through absorption and further metabolic conversion. The review highlights that acetate, propionate, and butyrate can influence local and systemic physiology, helping link intestinal chemistry to whole-body regulation. Their effects are therefore both immediate—through signalling pathways—and longer-lasting—through changes in gene regulation.

Mechanistically, the authors focus on receptor-mediated communication. SCFAs activate specific receptors on immune and metabolic cells, altering inflammatory tone and metabolic signalling. This receptor layer helps explain how intestinal events can reverberate in distant tissues that rely on tightly controlled energy and immune states.

Beyond receptors, SCFAs also affect epigenetics. By influencing chromatin-modifying enzymes and related regulatory networks, they can change how genes are expressed without altering DNA sequence. Such effects provide a plausible bridge between diet–microbiome interactions and sustained shifts in health trajectories.

The review further surveys tissue-specific outcomes, from effects on gut barrier function to immune regulation and metabolic homeostasis. Importantly, this heterogeneity helps reconcile why SCFAs sometimes show protective associations while other contexts yield mixed results—differences in dose, timing, microbial ecology, and host physiology can all matter.

When the evidence is assembled, the paper argues that SCFAs are strongly implicated in metabolic health and disease risk. Conditions such as obesity, insulin dysregulation, and inflammatory disorders have been linked to altered SCFA profiles, though causality remains an active area of investigation. The authors also discuss the limitations of current studies, including differences in measurement methods and confounding dietary factors.

Finally, the review evaluates translational opportunities. Rather than treating SCFAs as isolated supplements, it frames dietary and therapeutic strategies around pathways that enhance beneficial SCFA production or mimic their downstream effects. With low fibre intake becoming a public health concern worldwide, the work positions SCFAs as a key biological rationale for improving diet quality.

Overall, this Nature Metabolism review synthesizes what is known—and what is still uncertain—about SCFAs as central mediators between gut microbes and host biology. It suggests that targeting microbial fermentation and SCFA signalling could become a practical lever for metabolic disease prevention.

Subject of Research: Gut microbiota–derived short-chain fatty acids and their physiological roles
Article Title: Short-chain fatty acids
Article References: Dagbasi, A., Cai, M., Hirdaramani, A. et al. Short-chain fatty acids. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01579-9
DOI: https://doi.org/10.1038/s42255-026-01579-9
Image Credits: AI Generated

The mass extinction event known as the Great Dying, which occurred 252 million years ago, resulted in the loss of 96% of marine species, and for many years, scientists could not fully explain why certain animals disappeared while others survived.

That longstanding mystery may be closer to a resolution, thanks to a recent study in the Proceedings of the National Academy of Sciences, which suggests that differences in physiology, metabolism, and oxygen use helped determine which marine animals survived the catastrophe.

Stanford University researchers found that physiological differences largely determined which marine animals survived the end-Permian mass extinction after warming oceans lost much of their oxygen. Animals whose bodies could not meet rising oxygen demands, including brachiopods and crinoids that had long ruled the seafloor, had a hard time surviving as ocean temperatures rose and oxygen in the water dropped.

By contrast, mollusks and fish possessed body plans better suited to supplying oxygen as temperatures climbed, allowing them to survive in greater numbers.

“With this study, we essentially wanted to solve the mystery of why, when you go to the beach, you collect the shells of clams and snails rather than those of brachiopods,” said lead author Jose Andres Marquez, a former PhD student in the lab of Stanford’s Erik Anders Sperling.

Marquez and his team developed a model based on species’ metabolic oxygen balance and tested it using direct measurements of oxygen use in living relatives of both ancient groups. This included brachiopods collected from the San Juan Islands in Washington. Their results revealed that the risk of extinction closely aligned with how much oxygen a species required and how effectively it could transport oxygen within its body.

A Body Built for Survival

Modern sea animals, such as bivalves, gastropods, and fish, have become more active and muscular over time. Their hunting habits demand more oxygen, even under normal conditions. Although this could seem like a disadvantage during harsh times, it actually worked in their favor. When ocean temperatures rose and oxygen levels dropped during the Permian-Triassic period, these animals already relied on features such as gills, strong blood flow, and larger muscles to get more oxygen when needed.

On the other hand, Paleozoic animals like brachiopods and crinoids were slow-moving filter feeders that thrived in low-oxygen environments when things were stable. However, as temperatures rose, they required more oxygen, and their bodies could not keep up with the demand in the now-oxygen-poor waters.

“Our findings show that, across different organism groups, extinctions happened at much higher rates for those more vulnerable to increases in water temperature and decreases in oxygen availability,” Marquez said.

The findings support decades of evidence from the fossil record. Brachiopods, which once accounted for thousands of species, now number about 400. In contrast, bivalves have diversified and now account for between 10,000 and 15,000 species.

Settling the Debate

Sperling previously co-authored a 2018 study that identified oxygen loss and warming as the main causes of the Great Dying. However, that earlier research used only physiological data from modern species, so the results were influenced by data from commercially important fish and crustaceans rather than from the ancient groups that have largely disappeared. The new study addresses this limitation by directly measuring the physiology of living representatives of ancient animal groups, including brachiopods.

“This study is really the final nail in the coffin for what caused the Permian-Triassic mass extinction,” Sperling said.

A Familiar Climate

The environmental changes that led to the Great Dying began in oceans that were relatively cool and well-oxygenated, similar to present-day conditions. A massive release of volcanic carbon dioxide altered the atmosphere, driving global temperatures up by 8 to 12 degrees Celsius over several thousand years. By comparison, current climate projections estimate a rise of 1.5 to 4 degrees Celsius above preindustrial levels by 2100, but over a much shorter timescale. “The bad news is, we are on track for Permian-Triassic levels of warming in worst-case scenario projections,” Sperling said.

By comparing more groups of marine animals, the researchers hope to determine whether the physiological patterns that shaped Earth’s greatest mass extinction could help predict which species are most vulnerable as today’s oceans continue to warm. “We’re still at the point where we can change things and do something about it,” Sperling emphasized.

Austin Burgess is a writer and researcher with a background in sales, marketing, and data analytics. He holds an MBA, a Bachelor of Science in Business Administration, and a data analytics certification. His work focuses on breaking scientific developments, with an emphasis on emerging biology, cognitive neuroscience, and archaeological discoveries.

A newly published study in Nature Metabolism reports that brown fat can act as a hub of molecular messaging, using secreted microRNAs to coordinate physiology across the body. Researchers focused on brown adipose tissue—well known for its role in thermogenesis—and asked whether it also participates in long-distance communication via RNA signals.

To visualize and track these messages, the team employed brown-fat–specific RNA labeling in living systems. This strategy allowed them to connect RNA production within adipocytes to downstream effects elsewhere, moving beyond correlations toward a clearer map of inter-organ RNA traffic.

The central finding is the presence of a communication network mediated by microRNAs released from brown fat. These small regulatory RNAs appear to travel beyond the tissue of origin and engage gene-regulatory pathways in other organs, effectively relaying information about metabolic state.

Functionally, the work supports a model in which microRNA “dispatch” from thermogenic fat tunes cellular programs in remote targets. Such programs likely involve post-transcriptional regulation, a process microRNAs are known to influence by pairing with complementary sequences in messenger RNAs.

Importantly, the approach does not treat microRNAs as generic circulating molecules. Instead, the labeling confirms their brown-fat origin and strengthens the link between secretory RNA dynamics and systemic physiological outcomes.

The study also highlights the specificity of the messaging: not all RNAs are equally represented, and the labeled microRNA repertoire points to organized, tissue-defined signaling rather than random leakage.

Beyond mapping pathways, the results carry implications for metabolic disease research. If brown fat microRNAs can reshape gene expression in other organs, manipulating these signals could offer a route to modulate energy balance, insulin sensitivity, or inflammatory tone.

For now, the findings provide a blueprint for how RNA labelling combined with tissue specificity can uncover hidden layers of endocrine-like communication. As techniques improve, the field may move toward a broader “RNA connectome” linking organ behavior through secreted regulatory molecules.

Researchers describe their results as evidence that brown fat is not only a metabolic engine but also an information broadcaster. In the evolving landscape of viral-style science news, this discovery underscores how tiny RNA molecules can orchestrate large-scale biological conversations.

Subject of Research: Inter-organ communication via secreted microRNAs from brown adipose tissue.

Article Title: Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs.

Article References: Lino, M., Palermo-Ruiz, G., Efthymiou, V. et al. Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01558-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01558-0

New research from Columbia University found that adults who cut their sleep by about 80 minutes for six weeks packed on a pound (0.45 kg) and moved less during the day.

The post Losing Even 80 Minutes of Sleep a Night Linked to Weight Gain appeared first on Sci.News: Breaking Science News.

A new analysis of data from the Western Australian-based Raine Study suggests that two humble vegetable groups -- legumes and cruciferous vegetables -- may play an outsize role in protecting young adults from early cardiometabolic risk, though the benefits appear to diverge sharply between men and women.

The post Beans and Broccoli Linked to Lower Heart Risk in Young Adults appeared first on Sci.News: Breaking Science News.

In a groundbreaking discovery that could revolutionize the therapeutic approach to oral squamous cell carcinoma (OSCC), researchers have unveiled the intricate role of the circadian gene PER2 in modulating intracellular cholesterol synthesis. This novel mechanistic insight opens new avenues for chronotherapy, particularly enhancing the efficacy of simvastatin, a widely used cholesterol-lowering agent, in combating this aggressive form of cancer.

Oral squamous cell carcinoma remains a significant global health challenge, with limited advancements in effective treatment modalities over the past decades. The cancer’s high propensity for invasiveness and metastasis necessitates innovative strategies that go beyond conventional chemotherapy and radiotherapy. At the cellular level, the adaptation of metabolic pathways, including cholesterol biosynthesis, is increasingly recognized as a hallmark of cancer progression. Cholesterol not only supports membrane biogenesis in rapidly proliferating cancer cells but also acts as a precursor for vital signaling molecules that drive oncogenic pathways.

Central to this study is the circadian clock gene PER2 (Period Circadian Regulator 2), traditionally known for its role in maintaining the body’s biological rhythms. Beyond its canonical function in regulating sleep-wake cycles, PER2 has emerged as a multifaceted regulator of cellular metabolism and tumor suppression. The research team employed a combination of molecular biology techniques, transcriptomic analyses, and in vivo models to delineate how PER2 interfaces with the cholesterol synthesis machinery within cancer cells.

Their findings reveal that PER2 exerts a repressive effect on the mevalonate pathway, the critical metabolic cascade responsible for the generation of cholesterol. Specifically, PER2 downregulates key enzymatic nodes, including HMG-CoA reductase, thereby attenuating the flux of cholesterol precursors. This metabolic reprogramming is pivotal in depriving OSCC cells of essential lipid components required for their malignant behavior, effectively halting tumor growth and invasiveness.

Intriguingly, the study highlights that the endogenous oscillation of PER2 expression within cancer cells aligns with fluctuations in cholesterol synthesis activity. This temporal regulation suggests that the timing of therapeutic intervention could dramatically influence treatment outcomes. Leveraging this insight, the researchers investigated the concept of chronotherapy, administering simvastatin at specific circadian phases to synchronize drug action with the natural troughs in cholesterol biosynthesis dictated by PER2 rhythms.

Experimental paradigms demonstrated a pronounced enhancement in simvastatin’s anticancer efficacy when dosing corresponded with PER2-mediated suppression of cholesterol synthesis. This time-dependent treatment paradigm not only improved tumor regression in preclinical models but also minimized cytotoxic effects on healthy tissues, implying a superior therapeutic index for such chronomodulated regimens.

The implications of these findings extend beyond OSCC treatment, offering a proof-of-concept for integrating circadian biology with metabolic targeting in precision oncology. By harnessing the endogenous biological clock, it may be possible to optimize pharmacodynamics, reduce adverse effects, and overcome resistance mechanisms that have long hindered statin-based anticancer strategies.

Moreover, this research addresses a critical gap in understanding the interplay between clock genes and lipid metabolism in cancer biology. It proposes a cohesive framework where PER2 functions as a metabolic gatekeeper, orchestrating intracellular cholesterol synthesis in a temporally controlled manner that impacts tumorigenicity. The use of simvastatin, a clinically approved HMG-CoA reductase inhibitor, underscores the translational potential of this approach, facilitating rapid clinical adoption and testing in OSCC patients.

The study meticulously dissected the molecular circuitry underlying PER2’s regulatory role, identifying downstream effectors and transcriptional networks that culminate in cholesterol synthesis repression. Through chromatin immunoprecipitation and gene reporter assays, the team uncovered binding sites within promoters of key enzymes, confirming direct transcriptional control. This level of mechanistic detail enriches the conceptual landscape of circadian-metabolic interaction in cancer and provides novel biomarker candidates for therapeutic monitoring.

In vivo experiments employing xenograft models recapitulated the in vitro observations, demonstrating that modulation of PER2 expression modulates tumor growth trajectories. Mice receiving time-tailored simvastatin interventions showed significant tumor volume reduction and improved survival compared to conventional dosing schedules. These data illuminate the potential clinical benefits of integrating circadian timing in cancer drug administration protocols.

Beyond its immediate practical applications, this research invigorates the scientific dialogue around the circadian clock’s influence on cancer metabolism. It challenges researchers to rethink therapeutic strategies by factoring in the temporal dimension of tumor biology. Such chronotherapeutic interventions could ultimately lead to personalized, time-optimized cancer treatments that align with each patient’s molecular circadian profile.

Furthermore, the study invites exploration into combinatorial regimens where PER2 modulation and cholesterol pathway inhibitors act synergistically with immunotherapies or targeted agents. Understanding how circadian regulation interfaces with immune checkpoints and tumor microenvironment dynamics could unlock unprecedented multimodal approaches to OSCC management.

Given the clinical availability and well-characterized safety profile of statins, these findings carry significant translational momentum. Clinical trials designed to evaluate the chronotherapeutic efficacy of simvastatin in OSCC patients are a logical next step, potentially paving the way for novel treatment paradigms that leverage both metabolism and circadian biology.

In summary, this transformative work elucidates a critical metabolic checkpoint governed by the circadian gene PER2, fundamentally altering intracellular cholesterol synthesis and presenting a time-dependent vulnerability in oral squamous cell carcinoma. By aligning pharmacologic intervention with these biological rhythms, the efficacy of simvastatin is markedly enhanced, heralding a new era of chronobiology-informed oncology therapeutics.

As the scientific community continues to unravel the complexities of cancer metabolism and circadian regulation, studies like these underscore the paradigm-shifting potential of integrating diverse biological disciplines. The intersection of chronobiology and cancer metabolism exemplified by PER2’s role may well become a blueprint for future innovations aimed at conquering formidable malignancies such as OSCC.

---

Subject of Research: The role of the circadian gene PER2 in regulating intracellular cholesterol synthesis and enhancing the chronotherapeutic efficacy of simvastatin in oral squamous cell carcinoma.

Article Title: PER2 reprograms intracellular cholesterol synthesis to inhibit oral squamous cell carcinoma and the chronotherapeutic efficacy of simvastatin.

Article References:
Yin, S., Yang, F., Zhang, Z. et al. PER2 reprograms intracellular cholesterol synthesis to inhibit oral squamous cell carcinoma and the chronotherapeutic efficacy of simvastatin. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03209-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03209-5

University of Michigan Rogel Cancer Center researchers have unveiled a groundbreaking metabolic mechanism that colorectal cancer cells exploit to maintain exceptionally high iron levels, a discovery that opens promising avenues for targeted cancer therapies. Published recently in Cell Metabolism, this study provides an unprecedented insight into how tumor cells sidestep iron toxicity and evade a form of cell death known as ferroptosis, potentially revolutionizing the understanding of metal metabolism in cancer biology.

Colorectal cancer cells are known to harbor elevated iron concentrations, far surpassing those found in healthy cells. Iron is a double-edged sword in cellular physiology—essential for processes like DNA synthesis and cell proliferation but lethal in excess due to its propensity to generate harmful reactive oxygen species. Ordinarily, cells with excessive iron succumb to ferroptosis, a specialized form of oxidative cell death driven by iron-mediated lipid peroxidation. Tumor cells subvert this natural safeguard, sustaining iron overload without triggering their own demise, but how they achieve this has remained elusive—until now.

The investigative team led by Dr. Yatrik Shah, Horace W. Davenport Collegiate Professor of Physiology at Michigan Medicine, employed a metabolism-directed CRISPR screening approach to systematically dissect the pathways protecting colorectal cancer cells from iron-induced oxidative damage. Surprisingly, canonical ferroptotic enzymes, previously presumed central to this resistance, were found non-essential for tumor survival. This redirected focus led the scientists to explore mitochondrial metabolism more profoundly.

Their research unveiled that the mitochondrial enzyme complex II plays a pivotal role in safeguarding cancer cells from iron-induced toxicity. Complex II regulates coenzyme Q (CoQ) within mitochondria, a key antioxidant molecule that quells oxidative stress. By fine-tuning CoQ’s redox state, complex II effectively buffers the destructive potential of accumulated iron, preventing ferroptosis and enabling cancer cell proliferation. When researchers knocked out complex II in colorectal cancer models, iron toxicity became unmanageable for the tumor cells, leading to widespread cell death and marked tumor growth inhibition.

Crucially, complex II’s protective mechanism appears specific to the high-iron environment of cancer cells. In mouse models, disruption of complex II elicited negligible adverse effects on normal tissues, underscoring the therapeutic potential of selectively targeting this mitochondrial axis in colorectal cancer. This specificity addresses a significant hurdle in oncology: minimizing treatment toxicity while maximizing antitumor efficacy.

Further intricacies emerged as the study revealed a feedback loop wherein iron itself modulates complex II activity, suggesting a sophisticated regulatory axis that maintains iron homeostasis within tumors. This bidirectional interaction offers additional molecular targets for disrupting iron tolerance in cancer cells and deepening our understanding of tumor metabolism.

These findings represent a paradigm shift from earlier hypotheses centered on canonical ferroptosis regulators, highlighting the necessity of focusing on mitochondrial metabolism in cancer research. By leveraging sophisticated genome-editing tools and bioenergetic profiling, the Rogel Cancer Center team charted a novel course for drug discovery efforts aimed at crippling iron addiction—a hallmark of not only colorectal but potentially many other malignancies.

The next phase of this research endeavors to identify and develop potent inhibitors of complex II or its associated metabolic pathways. Given that dysregulated iron metabolism is a common vulnerability across diverse cancer types, these interventions could herald a new era of broad-spectrum anticancer strategies. Moreover, detailed characterization of iron complex II interplay might uncover additional metabolic dependencies exploitable for therapeutic gains.

This transformative research underscores the intricate metabolic adaptations that empower colorectal cancers to circumvent intrinsic iron toxicity constraints. By illuminating the heme-complex II axis as a linchpin in maintaining oxidative balance amid iron overload, it offers a highly selective target for the design of next-generation anticancer agents.

Researchers anticipate that combining complex II inhibition with other therapies may amplify treatment responses and overcome resistance mechanisms. As the quest to outsmart cancer evolves, this study reinforces the vital role of mitochondrial metabolism understanding in crafting innovative clinical interventions.

In sum, the University of Michigan team’s discovery of complex II’s role in buffering iron toxicity not only deciphers a long-standing biological enigma but also charts a compelling translational pathway. It epitomizes how fundamental metabolic insights can accelerate the development of precision treatments conferring hope to millions affected by colorectal cancer worldwide.

Subject of Research: Cells
Article Title: Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death
News Publication Date: June 17, 2026
Web References: http://dx.doi.org/10.1016/j.cmet.2026.04.020
References: “Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death,” Cell Metabolism, DOI: 10.1016/j.cmet.2026.04.020
Image Credits: Shah Lab, Rogel Cancer Center
Keywords: Colorectal cancer, iron metabolism, ferroptosis, complex II, coenzyme Q, mitochondrial metabolism, oxidative cell death, tumor metabolism, cancer therapy

A groundbreaking fluorescent reporter enabling real-time visualization of biologically active iron and oxygen at the single-cell level inside living organisms has been developed by researchers at the Institute of Science Tokyo. This revolutionary tool, named LiON (labile iron and oxygen notifier), ushers in a new era for cellular biology by offering unprecedented insight into the dynamic interplay and distribution of these essential elements within living tissues. Published in the esteemed journal Cell Reports Methods, this innovation promises to transform the study of fundamental physiological processes and complex diseases, from oncology and liver pathology to neurodegenerative disorders and aging.

Iron and oxygen are indispensable to cellular function, acting as core contributors to energy production, metabolic regulation, and DNA synthesis. Despite their vital roles, maintaining the delicate balance and spatial distribution of labile ferrous iron and reactive oxygen species remains critical, as disruptions often lead to cellular damage and disease. Historically, the challenge has been the absence of imaging tools capable of monitoring these elements within living cells at sufficient resolution, particularly differentiating biologically active forms from inert reservoirs.

Traditional methods of detecting iron, such as histochemical staining or mass spectrometry, require fixed tissue samples, offering only static snapshots devoid of temporal context. Although advanced clinical imaging modalities like magnetic resonance imaging enable in vivo iron mapping, they lack cellular resolution and fail to discriminate between active and stored iron pools. This limitation impairs the ability to study cellular heterogeneity and microenvironmental influences critical to disease pathogenesis.

To bridge this gap, the team led by Professor Toshiro Moroishi and doctoral researcher Ayato Maeda ingeniously exploited the iron- and oxygen-sensitive regulatory domain of FBXL5, a protein known to undergo degradation in low-iron and low-oxygen conditions. By genetically fusing this domain to a red fluorescent protein while coupling it with a stable green fluorescent protein, they engineered a ratiometric biosensor. Variations in red-to-green fluorescence ratios directly reflect intracellular labile iron and oxygen levels, enabling precise, quantitative assessments at single-cell resolution in living tissues.

Generating transgenic mice expressing LiON, the investigators revealed remarkable gradients and heterogeneity in iron and oxygen distribution across various organs and within homogeneous cell populations. For instance, they identified spatially distinct iron accumulation proximal to portal veins in the liver, highlighting areas susceptible to oxidative stress and metabolic dysfunction. These nuanced observations suggest complex regulatory mechanisms governing iron homeostasis that could not previously be elucidated in vivo.

Beyond fundamental biology, the capacity to monitor labile iron and oxygen in living systems has profound clinical implications. Iron dysregulation and hypoxia are hallmarks of cancer progression, neurodegeneration, and age-related tissue decline. The ability to dynamically track these parameters within specific cell types allows for the investigation of pathophysiological processes at an unprecedented scale, facilitating the development and evaluation of targeted therapies.

Importantly, the modular genetic design of LiON enables conditional activation in defined tissues or cell populations using well-established genetic tools. This versatility empowers researchers to tailor investigations according to disease models or biological questions, drastically expanding the utility of this fluorescent reporter across scientific disciplines. It also paves the way for high-throughput screening approaches and longitudinal studies previously unattainable.

Technically, the LiON sensor leverages competitive degradation pathways mediated by FBXL5’s hemerythrin-like domain, which senses iron and oxygen availability to regulate protein stability. When iron and oxygen are sufficient, FBXL5 remains stable, maintaining the red fluorescence. Under conditions of deficiency, FBXL5 is degraded, reducing red fluorescence and shifting the fluorescence ratio. By normalizing against stable green fluorescence, this ratiometric approach cancels out confounding factors such as expression levels or photobleaching, ensuring robust quantification.

Further development of LiON may enable integration with multiphoton or super-resolution microscopy, amplifying the ability to investigate cellular metabolism and microenvironmental niches in unprecedented detail. Moreover, its application in live imaging models can accelerate translational research by offering real-time insights into therapeutic interventions and disease progression, a vital step toward precision medicine.

The researchers emphasize that understanding heterogeneity in iron and oxygen management at the single-cell level will clarify diverse cellular responses within tissues, facilitating the identification of vulnerable or resistant cell populations. This information is invaluable for unraveling mechanisms underpinning complex diseases, optimizing drug delivery, and minimizing off-target effects.

As the first fluorescent reporter capable of in vivo, single-cell resolution imaging of labile iron and oxygen, LiON represents a transformative leap forward. The integration of this tool into mainstream biomedical research has the potential to catalyze breakthroughs spanning from fundamental cell biology to clinical therapeutics, establishing a new paradigm in the visualization and understanding of elemental biology.

In the words of Professor Moroishi, “LiON opens a window into cellular microenvironments that were previously invisible, enabling us to observe and quantify critical biochemical landscapes that dictate health and disease. We anticipate that this technology will become an indispensable asset across many branches of life science research.”

With the establishment of the Institute of Science Tokyo, a visionary new institution formed through the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, this breakthrough exemplifies a commitment to pioneering innovative science aimed at enhancing human well-being. The convergence of multidisciplinary expertise and cutting-edge technology exemplified by LiON underscores the promise of collaborative research to address some of the most pressing biomedical challenges of our time.

---

Subject of Research: Animals
Article Title: In vivo visualization of bioactive iron and oxygen using LiON, the labile iron and oxygen notifier
News Publication Date: 8-May-2026
Web References: DOI: 10.1016/j.crmeth.2026.101431
Image Credits: Institute of Science Tokyo
Keywords: Life sciences, Cell biology, Fluorescent proteins, Biomolecules, Biochemistry, Iron, Oxygen, Human health, Diseases and disorders, Neurodegenerative diseases, Cancer research, Clinical medicine

In the ongoing battle against prostate cancer, researchers have uncovered a biochemical pathway that promises to revolutionize treatment strategies. A recent study by Zhang, H., Feng, T., Lv, M., and colleagues, published in Cell Death Discovery, reveals how quinolinic acid, a metabolite derived from the enzyme HAAO, significantly influences androgen receptor (AR) signaling via an FDPS-dependent mechanism. This discovery not only deepens our understanding of prostate cancer biology but also highlights a novel avenue for enhancing the efficacy of combination therapies.

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, with androgen receptor signaling playing a pivotal role in disease progression and therapy resistance. Androgen deprivation therapies (ADT) have long been the frontline treatment; however, many patients eventually develop castration-resistant prostate cancer (CRPC), underscoring the urgent need for new molecular targets and therapeutic strategies. The study conducted by Zhang and colleagues brings to light the critical interplay between metabolites in the kynurenine pathway and AR signaling, potentially offering new hope for overcoming therapeutic resistance.

Central to their findings is quinolinic acid (QA), a metabolite produced downstream of 3-hydroxyanthranilic acid oxygenase (HAAO) activity within the kynurenine pathway of tryptophan metabolism. Quinolinic acid has traditionally been studied for its neurotoxic properties, but this research innovatively identifies QA as a key modulator within prostate cancer cells. The team demonstrated that HAAO expression is markedly elevated in prostate cancer tissues, correlating with advanced disease stages and poorer prognosis.

Mechanistically, quinolinic acid appears to fuel FDPS (farnesyl diphosphate synthase)-dependent androgen receptor signaling. FDPS is a crucial enzyme in the mevalonate pathway, responsible for the synthesis of isoprenoids, which are vital for protein prenylation and cellular proliferation. The researchers showed that elevated QA enhances FDPS activity, leading to increased AR signaling activity. This hyperactivation of AR signaling amplifies cancer cell growth and survival, facilitating resistance to standard therapies.

What makes this discovery particularly compelling is the demonstration that modulating levels of quinolinic acid can sensitize prostate cancer cells to combination therapeutic approaches. The study revealed that inhibiting HAAO or reducing quinolinic acid production diminishes FDPS-dependent AR signaling, thereby suppressing tumor cell proliferation and improving the effectiveness of anti-androgen drugs. These findings suggest a promising therapeutic window where targeting metabolic pathways can synergize with hormonal therapies to overcome resistance.

The implications of these results extend beyond a simple metabolic snapshot. They connect two major biological systems—the kynurenine pathway and the mevalonate pathway—each with independent significance in cancer biology but now linked through quinolinic acid’s regulatory effects. This metabolic crosstalk introduces a paradigm shift in how metabolic intermediates can be exploited to influence oncogenic signaling cascades.

Moreover, the study utilized a combination of advanced molecular techniques including transcriptomics, metabolomics, and functional assays in both in vitro and in vivo models. These comprehensive approaches validated the critical role of HAAO-derived quinolinic acid and its impact on FDPS expression and activity. Importantly, patient-derived xenografts and clinical data underscored the translational relevance of the findings, suggesting readiness for clinical exploration.

Therapeutically, the prospect of combining HAAO inhibitors or agents targeting quinolinic acid synthesis with established anti-androgen therapies such as enzalutamide marks a significant advancement. This combination strategy could potentially prevent or delay the onset of treatment resistance, a major hurdle in managing advanced prostate cancer. Additionally, the study hints at the broader possibility of targeting metabolic vulnerabilities in other androgen-driven cancers.

From a mechanistic perspective, the identification of quinolinic acid as an oncometabolite challenges previous notions relegating it to neurotoxicity roles. It invites further exploration of how metabolic byproducts can act as signaling molecules within the tumor microenvironment, influencing cancer cell behavior and treatment outcomes. This insight opens doors for novel biomarkers that can predict response to therapy and guide personalized medicine approaches.

Furthermore, the study paves the way to investigate whether similar metabolic dependencies exist in other malignancies where steroid hormone receptor signaling is critical. If so, the HAAO-FDPS-AR axis may become a universal target across multiple cancer types, broadening the scope of therapeutic interventions beyond prostate cancer alone.

On the molecular signaling axis, the team discovered that quinolinic acid’s impact on FDPS promotes AR nuclear translocation and transcriptional activity, leading to enhanced expression of AR target genes that drive proliferation and survival pathways. This detailed mechanistic insight provides concrete targets for pharmacological intervention and biomarker development.

This groundbreaking study also raises important questions about the metabolic plasticity of cancer cells and their ability to adapt biosynthetic pathways to sustain oncogenic signaling. Understanding how cancer cells leverage metabolites like quinolinic acid could illuminate resistance mechanisms and identify vulnerabilities exploitable by combination therapies.

In conclusion, the elucidation of HAAO-derived quinolinic acid as a central actor fueling FDPS-dependent androgen receptor signaling heralds a novel metabolic axis driving prostate cancer progression and therapy resistance. By bridging metabolic biochemistry and signal transduction, the research sets the stage for innovative treatment paradigms that combine metabolic inhibition with hormonal therapy, potentially transforming patient outcomes in prostate cancer and beyond.

Zhang and colleagues’ work exemplifies the power of integrative omics and translational research in unraveling complex cancer biology, inviting the scientific community to rethink how metabolic intermediates can be harnessed in the fight against malignancy. As research advances, the HAAO-quinolinic acid-FDPS-AR signaling axis may well become a cornerstone in precision oncology strategies targeting prostate cancer metabolism and hormone receptor signaling.

---

Subject of Research: Prostate cancer metabolism and androgen receptor signaling modulation by HAAO-derived quinolinic acid.

Article Title: HAAO-derived quinolinic acid fuels FDPS-dependent AR signaling and sensitizes prostate cancer to combination therapy.

Article References:
Zhang, H., Feng, T., Lv, M. et al. HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03203-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03203-x

In a mouse study conducted by scientists at the Dasman Diabetes Institute in Kuwait, rodents fed a sucrose-free diet developed insulin resistance, gut microbial imbalances and signs of fatty liver disease despite maintaining similar body weight.

The post Eliminating Sucrose from Low-Fat Diet Alters Gut Microbiome, Animal Study Suggests appeared first on Sci.News: Breaking Science News.

In new research, scientists sequenced and analyzed chromosome-level genomes of the Linnaeus’s two-toed sloth (Choloepus didactylus) and the southern anteater (Tamandua tetradactyla).

The post Secret to Sloths’ Slow Life May Lie in Ancient ‘Jumping Genes’ appeared first on Sci.News: Breaking Science News.

Scientists discovered a hidden gut-brain network that can change cravings when the body needs more protein. The body has a remarkable ability to recognize when it is missing important nutrients and adjust behavior accordingly. New research shows that the gut plays a much larger role in this process than previously understood, actively detecting protein shortages [...]

A new AI framework called MouseMapper allows scientists to examine disease-related changes across the entire body at cellular resolution. Obesity does much more than affect metabolism and fat storage. It also changes immune activity, nerve structure, and tissue organization throughout the body, raising the risk of conditions such as type 2 diabetes, cardiovascular disease, stroke, [...]

Scientists identified phosphatidylcholine loss as a key driver of mitochondrial aging and showed that restoring it can rejuvenate cellular energy networks. Why do cells age, and why do people gradually lose energy and vitality over time? Scientists have long focused on mitochondria, the tiny structures inside cells responsible for producing energy. Researchers now understand that [...]

In a small clinical trial, researchers at the Ohio State University found that a tomato juice rich in lycopene and soy isoflavones lowered several proteins linked to chronic inflammation, raising hopes for food-based therapies.

The post Tomato-Soy Drink May Help Fight Chronic Inflammation in Adults with Obesity appeared first on Sci.News: Breaking Science News.